1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Paclitaxel Injection Market
4. Market Overview
    4.1. Introduction
        4.1.1. Segment Definition
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Paclitaxel Injection Market Analysis and Forecast, 2017-2031
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Pricing Analysis
    5.2. Diseases Prevalence & Incidence Rate Globally and with the Key Countries
    5.3. Covid-19 Pandemic Impact on the Industry
6. Global Paclitaxel Injection Market Analysis and Forecast, by Application
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Application, 2017-2031
        6.3.1. Ovarian Carcinoma
        6.3.2. Breast Carcinoma
        6.3.3. Pancreatic Cancer
        6.3.4. Advanced Non-small Cell Lung Carcinoma
        6.3.5. Others (AIDS-related Kaposi’s sarcoma, etc.)
    6.4. Market Attractiveness Analysis, by Application
7. Global Paclitaxel Injection Market Analysis and Forecast, by Distribution Channel
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Distribution Channel, 2017-2031
        7.3.1. Hospital Pharmacies
        7.3.2. Online Pharmacies
        7.3.3. Retail Pharmacies
    7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Paclitaxel Injection Market Analysis and Forecast, by Region
    8.1. Key Findings
    8.2. Market Value Forecast, by Region
        8.2.1. North America
        8.2.2. Europe
        8.2.3. Asia Pacific
        8.2.4. Latin America
        8.2.5. Middle East & Africa
    8.3. Market Attractiveness Analysis, by Region
9. North America Paclitaxel Injection Market Analysis and Forecast
    9.1. Introduction
        9.1.1. Key Findings
    9.2. Market Value Forecast, by Application, 2017-2031
        9.2.1. Ovarian Carcinoma
        9.2.2. Breast Carcinoma
        9.2.3. Pancreatic Cancer
        9.2.4. Advanced Non-small Cell Lung Carcinoma
        9.2.5. Others (AIDS-related Kaposi’s sarcoma, etc.)
    9.3. Market Value Forecast, by Distribution Channel, 2017-2031
        9.3.1. Hospital Pharmacies
        9.3.2. Online Pharmacies
        9.3.3. Retail Pharmacies
    9.4. Market Value Forecast, by Country, 2017-2031
        9.4.1. U.S.
        9.4.2. Canada
    9.5. Market Attractiveness Analysis
        9.5.1. By Application
        9.5.2. By Distribution Channel
        9.5.3. By Country
10. Europe Paclitaxel Injection Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Application, 2017-2031
        10.2.1. Ovarian Carcinoma
        10.2.2. Breast Carcinoma
        10.2.3. Pancreatic Cancer
        10.2.4. Advanced Non-small Cell Lung Carcinoma
        10.2.5. Others (AIDS-related Kaposi’s sarcoma, etc.)
    10.3. Market Value Forecast, by Distribution Channel, 2017-2031
        10.3.1. Hospital Pharmacies
        10.3.2. Online Pharmacies
        10.3.3. Retail Pharmacies
    10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
        10.4.1. Germany
        10.4.2. U.K.
        10.4.3. France
        10.4.4. Italy
        10.4.5. Spain
        10.4.6. Rest of Europe
    10.5. Market Attractiveness Analysis
        10.5.1. By Application
        10.5.2. By Distribution Channel
        10.5.3. By Country/Sub-region
11. Asia Pacific Paclitaxel Injection Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Application, 2017-2031
        11.2.1. Ovarian Carcinoma
        11.2.2. Breast Carcinoma
        11.2.3. Pancreatic Cancer
        11.2.4. Advanced Non-small Cell Lung Carcinoma
        11.2.5. Others (AIDS-related Kaposi’s sarcoma, etc.)
    11.3. Market Value Forecast, by Distribution Channel, 2017-2031
        11.3.1. Hospital Pharmacies
        11.3.2. Online Pharmacies
        11.3.3. Retail Pharmacies
    11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
        11.4.1. China
        11.4.2. Japan
        11.4.3. India
        11.4.4. Australia & New Zealand
        11.4.5. Rest of Asia Pacific
    11.5. Market Attractiveness Analysis
        11.5.1. By Application
        11.5.2. By Distribution Channel
        11.5.3. By Country/Sub-region
12. Latin America Paclitaxel Injection Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Application, 2017-2031
        12.2.1. Ovarian Carcinoma
        12.2.2. Breast Carcinoma
        12.2.3. Pancreatic Cancer
        12.2.4. Advanced Non-small Cell Lung Carcinoma
        12.2.5. Others (AIDS-related Kaposi’s sarcoma, etc.)
    12.3. Market Value Forecast, by Distribution Channel, 2017-2031
        12.3.1. Hospital Pharmacies
        12.3.2. Online Pharmacies
        12.3.3. Retail Pharmacies
    12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
        12.4.1. Brazil
        12.4.2. Mexico
        12.4.3. Rest of Latin America
    12.5. Market Attractiveness Analysis
        12.5.1. By Application
        12.5.2. By Distribution Channel
        12.5.3. By Country/Sub-region
13. Middle East & Africa Paclitaxel Injection Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Application, 2017-2031
        13.2.1. Ovarian Carcinoma
        13.2.2. Breast Carcinoma
        13.2.3. Pancreatic Cancer
        13.2.4. Advanced Non-small Cell Lung Carcinoma
        13.2.5. Others (AIDS-related Kaposi’s sarcoma, etc.)
    13.3. Market Value Forecast, by Distribution Channel, 2017-2031
        13.3.1. Hospital Pharmacies
        13.3.2. Online Pharmacies
        13.3.3. Retail Pharmacies
    13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
        13.4.1. GCC Countries
        13.4.2. South Africa
        13.4.3. Rest of Middle East & Africa
    13.5. Market Attractiveness Analysis
        13.5.1. By Application
        13.5.2. By Distribution Channel
        13.5.3. By Country/Sub-region
14. Competition Landscape
    14.1. Market Player – Competition Matrix (by tier and size of companies)
    14.2. Market Share Analysis, by Company, 2021
    14.3. Company Profiles
        14.3.1. Accord Healthcare Ireland Ltd.
            14.3.1.1. Company Overview
            14.3.1.2. Financial Overview
            14.3.1.3. Product Portfolio
            14.3.1.4. Business Strategies
            14.3.1.5. Recent Developments
        14.3.2. Alembic Pharmaceuticals Limited
            14.3.2.1. Company Overview
            14.3.2.2. Financial Overview
            14.3.2.3. Product Portfolio
            14.3.2.4. Business Strategies
            14.3.2.5. Recent Developments
        14.3.3. American Regent, Inc.
            14.3.3.1. Company Overview
            14.3.3.2. Financial Overview
            14.3.3.3. Product Portfolio
            14.3.3.4. Business Strategies
            14.3.3.5. Recent Developments
        14.3.4. Dash Pharmaceuticals LLC
            14.3.4.1. Company Overview
            14.3.4.2. Financial Overview
            14.3.4.3. Product Portfolio
            14.3.4.4. Business Strategies
            14.3.4.5. Recent Developments
        14.3.5. Dr. Reddy’s Laboratories Ltd.
            14.3.5.1. Company Overview
            14.3.5.2. Financial Overview
            14.3.5.3. Product Portfolio
            14.3.5.4. Business Strategies
            14.3.5.5. Recent Developments
        14.3.6. Fresenius Kabi India Pvt. Ltd.
            14.3.6.1. Company Overview
            14.3.6.2. Financial Overview
            14.3.6.3. Product Portfolio
            14.3.6.4. Business Strategies
            14.3.6.5. Recent Developments
        14.3.7. Gland Pharma Limited
            14.3.7.1. Company Overview
            14.3.7.2. Financial Overview
            14.3.7.3. Product Portfolio
            14.3.7.4. Business Strategies
            14.3.7.5. Recent Developments
        14.3.8. Heter
            14.3.8.1. Company Overview
            14.3.8.2. Financial Overview
            14.3.8.3. Product Portfolio
            14.3.8.4. Business Strategies
            14.3.8.5. Recent Developments
        14.3.9. Intas Pharmaceuticals Ltd.
            14.3.9.1. Company Overview
            14.3.9.2. Financial Overview
            14.3.9.3. Product Portfolio
            14.3.9.4. Business Strategies
            14.3.9.5. Recent Developments
        14.3.10. MSN Laboratories
            14.3.10.1. Company Overview
            14.3.10.2. Financial Overview
            14.3.10.3. Product Portfolio
            14.3.10.4. Business Strategies
            14.3.10.5. Recent Developments
        14.3.11. Panacea Biotec
            14.3.11.1. Company Overview
            14.3.11.2. Financial Overview
            14.3.11.3. Product Portfolio
            14.3.11.4. Business Strategies
            14.3.11.5. Recent Developments
        14.3.12. Pfizer, Inc.
            14.3.12.1. Company Overview
            14.3.12.2. Financial Overview
            14.3.12.3. Product Portfolio
            14.3.12.4. Business Strategies
            14.3.12.5. Recent Developments
        14.3.13. Sandoz International GmbH
            14.3.13.1. Company Overview
            14.3.13.2. Financial Overview
            14.3.13.3. Product Portfolio
            14.3.13.4. Business Strategies
            14.3.13.5. Recent Developments
        14.3.14. Teva Pharmaceutical Industries Ltd.
            14.3.14.1. Company Overview
            14.3.14.2. Financial Overview
            14.3.14.3. Product Portfolio
            14.3.14.4. Business Strategies
            14.3.14.5. Recent Developments
        14.3.15. Zydus Group
            14.3.15.1. Company Overview
            14.3.15.2. Financial Overview
            14.3.15.3. Product Portfolio
            14.3.15.4. Business Strategies
            14.3.15.5. Recent Developments
        14.3.16. Apotex Corp.
            14.3.16.1. Company Overview
            14.3.16.2. Financial Overview
            14.3.16.3. Product Portfolio
            14.3.16.4. Business Strategies
            14.3.16.5. Recent Developments
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


 
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			